Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 2, 2006, Pages 237-241

  Zhang, Jian Lin ^a   Guo, Jian Jin ^a   Zhang, Zi Yan ^a   Jing, Yi Xin ^a   Zhang, Lin ^a   Guo, Rui ^a   Yan, Ping ^a   Cheng, Niu Liang ^a   Niu, Bo ^a   Xie, Jun ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus surface antigen; Phage antibody library; Phage display technology; Single chain fragment variable

Indexed keywords

COMPLEMENTARY DNA; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACTERIUM COLONY; BINDING AFFINITY; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE AMPLIFICATION; GENETIC TRANSFECTION; HEPATITIS B; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PHAGE DISPLAY; PHAGEMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; RNA ISOLATION; VOLUNTEER;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MASS SCREENING; PEPTIDE LIBRARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33744794598     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Perrillo RP. Overview of treatment of hepatitis B:key approaches and clinical challenges. Semin Liver Dis 2004;24:23-29.
2. Tiollais P, Buendia MA. Hepatitis B virus. Sci AM 1991; 264:116-123.
3. Shepard CW, Finelli L. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J 2005;24:755-760.
4. Hui AY, Sung JJ. Advances in chronic viral hepatitis. Curr Opin Infect Dis 2005;18:400-416.
5. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005;21:1845-1856.
6. Husa P, Plisek S, Sperl J. Diagnostic and treatment for chronic infection of hepatitis B virus. Klin Mikrobiol Infekc Lek 2005;11:138-143.
7. Ergunay K. Occult hepatitis B infections. Mikrobiyol Bul 2005;39:241-249.
8. Simons C, Wu Q, Htar TT. Recent advances in antiviral nucleoside and nucleotide therapeutics. Curr Top Med Chem 2005;5:1191-1203.
9. Virovic L, Wu CH, Konishi M, Wu GY. Novel delivery methods for treatment of viral hepatitis: an update. Expert Opin Drug Deliv 2005;2:707-717.
10. Nielsen FF. Hepatitis B vaccinations of medical students. Ugeskr Laeger 2005;167:4011.
11. Johns M, George AJ, Ritter MA. In vivo selection of ScFv from phage display libraries. J Immunol Methods 2000;239: 137-151.
12. Azzazy HM, Highsmith WE Jr. Phage display technology: Clinical applications and recent innovations. Clin Biochem 2002;35:425-445.
13. Watkins NA, Ouwehand WH. Introduction to antibody engineering and phage display. Vox Sang 2000;78:72-79.
14. Stadler BM. Antibody productions without animals. Dev Biol-Stand 1999;101:45-48.
15. Arndt MA, Krauss J, Rybak SM. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004;578:257-261.
16. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. Antibody phage display technology and its applications. Immunotechnology 1998;4:1-20.
17. Jermutus L. Phage Display Technologies-SMi Conference. 23-24 January 2002, London, UK. IDrugs 2002;5:203-205.
18. Killeen GF, Foy BD, Frohn RH. Enrichment of a single clone from a high diversity library of phage-displayed antibodies by panning with Anopheles gambiae (Diptera: Culicidae) midgut homogenate. Bull Entomol Res 2003;93:31-37.
19. Itoh K, Nakagomi O, Suzuki K. Recombinant human monoclonal Fab fragments against rotavirus from phage display combinatorial libraries Biochem (Tokyo) 1999;125:123-129.
20. Li HP, Zheng YL, Zhou H. Screening the antibody mimic peptide binding to hepatocellular carcinoma cells by phage display technique. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2005;21:452-455.
21. Liu J, Huang HL, Jiang SD. Antibody phage display technology: realities approaching to the dream. Yi Chuan 2002;24: 90-94.
22. Borysowski J, Gorski A. Phage-display technology and its application to experimental ontological therapy Postepy. Hig Med Dosw 2004;58:100-107.
23. Hoogenboom HR. Overview of antibody phage-display technology and its applications. Methods Mol Biol 2002;178:1-37.
24. Uchiyama F, Tanaka Y, Tokui N. Designing scaffolds of peptides for phage display libraries. J Biosci Bioeng 2005;99: 448-456.
25. Zhang ZC, Hu XJ, Yang Q. Generation of high affinity human single-chain antibody against PreS1 of hepatitis B virus from immune phage-display antibody library. Hepatobiliary Pancreat Dis Int 2004;3:77-81.
26. Van Kuppevelt TH, Jenniskens GJ, Veerkamp JH, ten Dam GB, Dennissen MA. Phage display technology to obtain antiheparan sulfate antibodies. Methods Mol Biol 2001;171:519-534.
27. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-450.
28. Xu L, Tang WH, H. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferring receptor ScFv. Mol Med 2001;7:723-734.
29. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24:45-53.
30. Mohr L, Yeung A, Wands JR. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 2004;127: 225-231.